Safinamide-d4, CAS 2748522-33-8

Safinamide-d4, CAS 2748522-33-8
Artikelnummer
CAY28490
Verpackungseinheit
1 mg
Hersteller
Cayman Chemical

Verfügbarkeit: wird geladen...
Preis wird geladen...
Formulation: A solid

Formal Name: 2S-[[[4-[(3-fluorophenyl)methoxy]phenyl-2,3,5,6-d4]methyl]amino]-propanamide

Purity: ≥99% deuterated forms (d1-d4)

Formula Markup: C17H15D4FN2O2

Formula Weight: 306,4

Shelf life (days): 1460

CAS Number: 2748522-33-8

Notes: Safinamide-d4 is intended for use as an internal standard for the quantification of safinamide (Item No. 21546) by GC- or LC-MS. Safinamide is an inhibitor of monoamine oxidase B (MAO-B; IC50 = ~0.1 μM).{33890} It is selective for MAO-B over MAO-A (IC50 = >10 μM). It also inhibits radioligand binding to sodium channel binding site 2, sigma-1, and sigma-2 receptors in rat brain membranes (IC50s = 8.2, 0.019, and 1.59 μM, respectively).{46371} Safinamide inhibits high voltage-activated calcium currents and depolarization-induced tetrodotoxin-sensitive fast sodium currents in rat hippocampal neurons in a concentration-dependent manner. It inhibits veratrine-induced glutamate release in rat hippocampal slices (IC50 = 56 μM). Safinamide inhibits maximal electroshock-induced tonic extension seizures in mice and rats (ED50s = 8 and 11.8 mg/kg, p.o.) as well as maximal seizures induced by bicuculline (Item No. 11727), picrotoxin (Item No. 20771), 3-mercaptopropionic acid, and strychnine in mice (ED50s = 26.9, 60.6, 21.5, and 104.1 mg/kg, p.o., respectively).{46372} Formulations containing safinamide have been used as adjunctive treatments to levodopa and carbidopa in the treatment of “off” episodes associated with Parkinson’s disease.
Mehr Informationen
Artikelnummer CAY28490
Hersteller Cayman Chemical
Hersteller Artikelnummer 28490-1
Green Labware Nein
Verpackungseinheit 1 mg
Mengeneinheit STK
Methode GC-MS, LC-MS, Isotopenmarkierung
Produktinformation (PDF) Download
MSDS (PDF) Download